Cargando…

Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns

Assessment of measurable residual disease (MRD) upon treatment of acute myeloid leukemia (AML) remains challenging. It is usually addressed by highly sensitive PCR- or sequencing-based screening of specific mutations, or by multiparametric flow cytometry. However, not all patients have suitable muta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Božić, Tanja, Kuo, Chao-Chung, Hapala, Jan, Franzen, Julia, Eipel, Monika, Platzbecker, Uwe, Kirschner, Martin, Beier, Fabian, Jost, Edgar, Thiede, Christian, Wagner, Wolfgang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727289/ https://www.ncbi.nlm.nih.gov/pubmed/34131280 http://dx.doi.org/10.1038/s41375-021-01316-z

Ejemplares similares

Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia
por: Jentzsch, Madlen, et al.
Publicado: (2019)

PRDM8 reveals aberrant DNA methylation in aging syndromes and is relevant for hematopoietic and neuronal differentiation
por: Cypris, Olivia, et al.
Publicado: (2020)

DNA-methylation in C1R is a prognostic biomarker for acute myeloid leukemia
por: Božić, Tanja, et al.
Publicado: (2015)

Impaired Overall Survival in Young Patients With Acute Myeloid Leukemia and Variants in Genes Predisposing for Myeloid Malignancies
por: Kirschner, Martin, et al.
Publicado: (2022)

Epigenetic age predictions based on buccal swabs are more precise in combination with cell type-specific DNA methylation signatures
por: Eipel, Monika, et al.
Publicado: (2016)

Genetic barcoding reveals clonal dominance in iPSC-derived mesenchymal stromal cells
por: Hollmann, Jonathan, et al.
Publicado: (2020)

Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study
por: Scott, Stuart, et al.
Publicado: (2023)

Variants of DNMT3A cause transcript-specific DNA methylation patterns and affect hematopoiesis
por: Božić, Tanja, et al.
Publicado: (2018)

The Genomic Landscape of Myeloid Malignancies: Options for Pan-myeloid Therapies?
por: Heidel, Florian H., et al.
Publicado: (2021)

Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia
por: Röhnert, Maximilian A., et al.
Publicado: (2022)

Measurable residual disease in chronic myeloid leukemia
por: Branford, Susan, et al.
Publicado: (2022)

Epigenetic age-predictor for mice based on three CpG sites
por: Han, Yang, et al.
Publicado: (2018)

Lipidomic approach for stratification of acute myeloid leukemia patients
por: Stefanko, Adam, et al.
Publicado: (2017)

Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia
por: Kayser, Sabine, et al.
Publicado: (2023)

Aberrant methylation of the M-type phospholipase A(2) receptor gene in leukemic cells
por: Menschikowski, Mario, et al.
Publicado: (2012)

P497: CLINICAL OUTCOMES OF NPM1-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) RELAPSE AFTER ACHIEVEMENT OF A FIRST MRD-NEGATIVE REMISSION
por: Jentzsch, Madlen, et al.
Publicado: (2023)

How Azanucleosides Affect Myeloid Cell Fate
por: Stein, Anna, et al.
Publicado: (2022)

Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study
por: Mittelman, Moshe, et al.
Publicado: (2023)

Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning
por: Eckardt, Jan-Niklas, et al.
Publicado: (2022)

Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia
por: Roloff, Gregory W., et al.
Publicado: (2017)

Angiogenesis and Minimal Residual Disease in Patients with Acute Myeloid Leukemia
por: Nematollahi, Pardis, et al.
Publicado: (2020)

Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia
por: Vonk, Christian M., et al.
Publicado: (2021)

Measurable Residual Disease in High-Risk Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2022)

Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia
por: Azenkot, Tali, et al.
Publicado: (2022)

Improved detection of measurable residual disease in acute myeloid leukemia
por: Zhang, Xuan, et al.
Publicado: (2023)

Aberrant DNA hypermethylation of the ITIH5 tumor suppressor gene in acute myeloid leukemia
por: Oing, Christoph, et al.
Publicado: (2011)

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4
por: Kayser, Sabine, et al.
Publicado: (2022)

DNA methylation in PRDM8 is indicative for dyskeratosis congenita
por: Weidner, Carola I., et al.
Publicado: (2016)

Outcomes of Older Patients with NPM1 Mutated and FLT3-ITD Negative Acute Myeloid Leukemia Receiving Allogeneic Transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2020)

New targeted approaches for epigenetic age predictions
por: Han, Yang, et al.
Publicado: (2020)

Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape
por: Hsieh, Ya-Ching, et al.
Publicado: (2021)

Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies
por: Platzbecker, Uwe, et al.
Publicado: (2022)

Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
por: Eckardt, Jan-Niklas, et al.
Publicado: (2023)

Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia
por: Yoest, Jennifer M., et al.
Publicado: (2020)

Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease
por: Maurillo, Luca, et al.
Publicado: (2019)

Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
por: Aitken, Marisa J. L., et al.
Publicado: (2021)

Delving the depths of measurable residual disease negativity in acute myeloid leukemia
por: Freeman, Sylvie D.
Publicado: (2022)

The present and future of measurable residual disease testing in acute myeloid leukemia
por: Blachly, James S., et al.
Publicado: (2022)

Role of Measurable Residual Disease in Older Adult Acute Myeloid Leukemia
por: Li, Xueyao, et al.
Publicado: (2023)

Clinical Implications of the FLT3-ITD Allelic Ratio in Acute Myeloid Leukemia in the Context of an Allogeneic Stem Cell Transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_556daj8q4hjoamvbrignhp47sa